As scientists across the U.S. face increasing uncertainty due to funding freezes and mass layoffs at health agencies, German ...

J&J’s new pivotal study in coronary artery disease, dubbed FORWARD CAD, will test a cardiac-focused version of the Javelin as ...

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on ...

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

| Facing “build versus buy,” or “rent versus own” for integration? Get a guide to the considerations for your organization’s ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. | GSK has continued ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Shortly after President Donald Trump took office this January, the White House rolled out an initiative designed to slash ...

Relay Therapeutics has laid off about 70 employees, the biotech's third round of cuts in less than a year.  | Relay ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.